专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5756103A Alvac canarypox virus recombinants comprising heterlogous inserts 失效
标题翻译： Alvac金丝雀痘病毒重组体包含杂种插入物
公开(公告)号：US5756103A
公开(公告)日：1998-05-26
申请号：US457007
申请日：1995-06-01
申请人： Enzo Paoletti , Marion E. Perkus , Jill Taylor , James Tartaglia , Elizabeth K. Norton , Michel Riviere , Charles de Taisne , Keith J. Limbach , Gerard P. Johnson , Steven E. Pincus , William I. Cox , Jean-Christophe Francis Audonnet , Russell Robert Gettig
发明人： Enzo Paoletti , Marion E. Perkus , Jill Taylor , James Tartaglia , Elizabeth K. Norton , Michel Riviere , Charles de Taisne , Keith J. Limbach , Gerard P. Johnson , Steven E. Pincus , William I. Cox , Jean-Christophe Francis Audonnet , Russell Robert Gettig
IPC分类号： A61K39/12 , A61K39/00 , A61K39/08 , A61K39/15 , A61K39/165 , A61K39/17 , A61K39/175 , A61K39/205 , A61K39/21 , A61K39/23 , A61K39/245 , A61K39/275 , A61K39/285 , A61K39/29 , A61P31/04 , A61P31/12 , A61P31/14 , A61P31/16 , A61P31/18 , A61P31/20 , A61P31/22 , C07H21/04 , C07K1/00 , C07K14/015 , C07K14/02 , C07K14/03 , C07K14/035 , C07K14/045 , C07K14/05 , C07K14/06 , C07K14/065 , C07K14/07 , C07K14/11 , C07K14/12 , C07K14/125 , C07K14/145 , C07K14/15 , C07K14/155 , C07K14/16 , C07K14/175 , C07K14/18 , C07K14/33 , C12N7/00 , C12N7/01 , C12N7/04 , C12N7/08 , C12N15/00 , C12N15/09 , C12N15/86 , C12N15/863 , C12P21/06 , C12R1/93
CPC分类号： C12N15/86 , C07K14/005 , C07K14/33 , A61K2039/5254 , A61K39/00 , C07K2319/00 , C07K2319/02 , C07K2319/40 , C12N2710/16122 , C12N2710/16222 , C12N2710/16622 , C12N2710/16722 , C12N2710/24022 , C12N2710/24043 , C12N2710/24122 , C12N2710/24143 , C12N2730/10122 , C12N2740/13022 , C12N2740/15022 , C12N2740/16122 , C12N2740/16222 , C12N2750/14322 , C12N2760/12122 , C12N2760/16122 , C12N2760/18122 , C12N2760/18422 , C12N2760/18722 , C12N2760/20122 , C12N2770/24122 , C12N2770/24322 , Y10S530/826
摘要： What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.
摘要翻译：描述的是具有增强的安全性的修饰载体，例如重组痘病毒，特别是重组痘苗病毒。修饰的重组病毒具有在其中灭活的非必需病毒编码的遗传功能，使得病毒具有减毒毒力。在一个实施方案中，通过删除编码毒力因子的开放阅读框来使遗传功能失活。在另一个实施方案中，通过插入失活编码毒力因子的开放阅读框来使遗传功能失活。还描述了含有修饰的重组病毒的疫苗，其具有在其中灭活的非必需的病毒编码的遗传功能，使得疫苗与已知的重组病毒疫苗相比具有提高的安全性水平。

2. 发明授权

US5766599A Trova fowl pox virus recombinants comprising heterologous inserts 失效
标题翻译：特洛瓦家禽痘病毒重组体包含异源插入物
公开(公告)号：US5766599A
公开(公告)日：1998-06-16
申请号：US458101
申请日：1995-06-01
申请人： Enzo Paoletti , Marion E. Perkus , Jill Taylor , James Tartaglia , Elizabeth K. Norton , Michel Riviere , Charles de Taisne , Keith J. Limbach , Gerard P. Johnson , Steven E. Pincus , William I. Cox , Jean-Christophe Francis Audonnet , Russell Robert Gettig
发明人： Enzo Paoletti , Marion E. Perkus , Jill Taylor , James Tartaglia , Elizabeth K. Norton , Michel Riviere , Charles de Taisne , Keith J. Limbach , Gerard P. Johnson , Steven E. Pincus , William I. Cox , Jean-Christophe Francis Audonnet , Russell Robert Gettig
IPC分类号： A61K39/12 , A61K39/00 , A61K39/08 , A61K39/15 , A61K39/165 , A61K39/17 , A61K39/175 , A61K39/205 , A61K39/21 , A61K39/23 , A61K39/245 , A61K39/275 , A61K39/285 , A61K39/29 , A61P31/04 , A61P31/12 , A61P31/14 , A61P31/16 , A61P31/18 , A61P31/20 , A61P31/22 , C07H21/04 , C07K1/00 , C07K14/015 , C07K14/02 , C07K14/03 , C07K14/035 , C07K14/045 , C07K14/05 , C07K14/06 , C07K14/065 , C07K14/07 , C07K14/11 , C07K14/12 , C07K14/125 , C07K14/145 , C07K14/15 , C07K14/155 , C07K14/16 , C07K14/175 , C07K14/18 , C07K14/33 , C12N7/00 , C12N7/01 , C12N7/04 , C12N7/08 , C12N15/00 , C12N15/09 , C12N15/86 , C12N15/863 , C12P21/06 , C12R1/93
CPC分类号： C12N15/86 , C07K14/005 , C07K14/33 , A61K2039/5254 , A61K39/00 , C07K2319/00 , C07K2319/02 , C07K2319/40 , C12N2710/16122 , C12N2710/16222 , C12N2710/16622 , C12N2710/16722 , C12N2710/24022 , C12N2710/24043 , C12N2710/24122 , C12N2710/24143 , C12N2730/10122 , C12N2740/13022 , C12N2740/15022 , C12N2740/16122 , C12N2740/16222 , C12N2750/14322 , C12N2760/12122 , C12N2760/16122 , C12N2760/18122 , C12N2760/18422 , C12N2760/18722 , C12N2760/20122 , C12N2770/24122 , C12N2770/24322 , Y10S530/826
摘要： What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.
摘要翻译：描述的是具有增强的安全性的修饰载体，例如重组痘病毒，特别是重组痘苗病毒。修饰的重组病毒具有在其中灭活的非必需病毒编码的遗传功能，使得病毒具有减毒毒力。在一个实施方案中，通过删除编码毒力因子的开放阅读框来使遗传功能失活。在另一个实施方案中，通过插入失活编码毒力因子的开放阅读框来使遗传功能失活。还描述了含有在其中灭活的非必需病毒编码的遗传功能的修饰的重组病毒的疫苗，使得疫苗与已知重组病毒疫苗相比具有提高的安全性水平。

3. 发明授权

US5762938A Modified recombinant vaccinia virus and expression vectors thereof 失效
标题翻译：改良的重组痘苗病毒及其表达载体
公开(公告)号：US5762938A
公开(公告)日：1998-06-09
申请号：US709209
申请日：1996-08-21
申请人： Enzo Paoletti , Marion E. Perkus , Jill Taylor , James Tartaglia , Elizabeth K. Norton , Michel Riviere , Charles de Taisne , Keith J. Limbach , Gerard P. Johnson , Steven E. Pincus , William I. Cox , Jean-Christophe Francis Audonnet , Russell Robert Gettig
发明人： Enzo Paoletti , Marion E. Perkus , Jill Taylor , James Tartaglia , Elizabeth K. Norton , Michel Riviere , Charles de Taisne , Keith J. Limbach , Gerard P. Johnson , Steven E. Pincus , William I. Cox , Jean-Christophe Francis Audonnet , Russell Robert Gettig
IPC分类号： A61K39/12 , A61K39/00 , A61K39/08 , A61K39/15 , A61K39/165 , A61K39/17 , A61K39/175 , A61K39/205 , A61K39/21 , A61K39/23 , A61K39/245 , A61K39/275 , A61K39/285 , A61K39/29 , A61P31/04 , A61P31/12 , A61P31/14 , A61P31/16 , A61P31/18 , A61P31/20 , A61P31/22 , C07H21/04 , C07K1/00 , C07K14/015 , C07K14/02 , C07K14/03 , C07K14/035 , C07K14/045 , C07K14/05 , C07K14/06 , C07K14/065 , C07K14/07 , C07K14/11 , C07K14/12 , C07K14/125 , C07K14/145 , C07K14/15 , C07K14/155 , C07K14/16 , C07K14/175 , C07K14/18 , C07K14/33 , C12N7/00 , C12N7/01 , C12N7/04 , C12N7/08 , C12N15/00 , C12N15/09 , C12N15/86 , C12N15/863 , C12P21/06 , C12R1/93
CPC分类号： C12N15/86 , C07K14/005 , C07K14/33 , A61K2039/5254 , A61K39/00 , C07K2319/00 , C07K2319/02 , C07K2319/40 , C12N2710/16122 , C12N2710/16222 , C12N2710/16622 , C12N2710/16722 , C12N2710/24022 , C12N2710/24043 , C12N2710/24122 , C12N2710/24143 , C12N2730/10122 , C12N2740/13022 , C12N2740/15022 , C12N2740/16122 , C12N2740/16222 , C12N2750/14322 , C12N2760/12122 , C12N2760/16122 , C12N2760/18122 , C12N2760/18422 , C12N2760/18722 , C12N2760/20122 , C12N2770/24122 , C12N2770/24322 , Y10S530/826
摘要： What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.
摘要翻译：描述的是具有增强的安全性的修饰载体，例如重组痘病毒，特别是重组痘苗病毒。修饰的重组病毒具有在其中灭活的非必需病毒编码的遗传功能，使得病毒具有减毒毒力。在一个实施方案中，通过删除编码毒力因子的开放阅读框来使遗传功能失活。在另一个实施方案中，通过插入失活编码毒力因子的开放阅读框来使遗传功能失活。还描述了含有在其中灭活的非必需病毒编码的遗传功能的修饰的重组病毒的疫苗，使得疫苗与已知重组病毒疫苗相比具有提高的安全性水平。

4. 发明授权

US06214353B1 Malaria recombinant poxvirus vaccine 失效
标题翻译：疟疾重组痘病毒疫苗
公开(公告)号：US06214353B1
公开(公告)日：2001-04-10
申请号：US09083366
申请日：1998-05-21
申请人： Enzo Paoletti , Charles de Taisne , Sandra Chang , George Hui , Wasim A. Siddigui
发明人： Enzo Paoletti , Charles de Taisne , Sandra Chang , George Hui , Wasim A. Siddigui
IPC分类号： A61K39285
CPC分类号： C07K14/445 , A61K39/00 , C07K2319/00 , C12N2799/023 , Y02A50/412
摘要： What is described is a recombinant poxvirus, such as vaccinia virus, containing foreign DNA from Plasmodium Merozoite Surface Antigen 1. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine.
摘要翻译：描述的是重组痘病毒，例如痘苗病毒，其含有来自裂殖酵母表面抗原的外源DNA 1.还描述了含有重组痘病毒的疫苗，用于在接种疫苗的宿主动物中诱导免疫应答。

5. 发明授权

US5756101A Malaria recombinant poxvirus 失效
标题翻译：疟疾重症痘病毒
公开(公告)号：US5756101A
公开(公告)日：1998-05-26
申请号：US178476
申请日：1994-01-07
申请人： Enzo Paoletti , Charles de Taisne , Sandra Chang , George Hui , Wasim Siddiqui
发明人： Enzo Paoletti , Charles de Taisne , Sandra Chang , George Hui , Wasim Siddiqui
IPC分类号： A61K39/00 , A61P33/06 , C07K14/445 , C12N7/01 , A61K39/015 , A61K39/285 , C12P21/02
CPC分类号： C07K14/445 , A61K39/00 , C07K2319/00 , C12N2799/023
摘要： What is described is a recombinant poxvirus, such as vaccinia virus, containing foreign DNA from Plasmodium Merozoite Surface Antigen 1. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine.
摘要翻译：描述的是重组痘病毒，例如痘苗病毒，其含有来自裂殖酵母表面抗原的外源DNA 1.还描述了含有重组痘病毒的疫苗，用于在接种疫苗的宿主动物中诱导免疫应答。

6. 发明授权

US5766597A Malaria recombinant poxviruses 失效
标题翻译：疟疾重症痘病毒
公开(公告)号：US5766597A
公开(公告)日：1998-06-16
申请号：US257073
申请日：1994-06-09
申请人： Enzo Paoletti , Charles de Taisne , John A. Tine
发明人： Enzo Paoletti , Charles de Taisne , John A. Tine
IPC分类号： A61K38/00 , A61K39/00 , A61K39/015 , A61K39/275 , A61K39/285 , C07K14/445 , C12N7/01
CPC分类号： C07K14/445 , A61K38/00 , A61K39/00
摘要： What is described is a recombinant poxvirus, such as vaccinia or canarypox virus, containing foreign DNA from Plasmodium such as coding for at least one of CSP, PfSSP2, LSA-1, LSA-1-repeatless, MSA-1, SERA, AMA-1, Pfs25, MSA-1 N-terminal p83 and MSA-1 C-terminal gp42. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine. Preferred recombinants have attenuated virulence. In certain embodiments the vaccinia has deleted or disrupted the thymidine kinase gene, the hemorrhagic region, the A type inclusion body region, the host range gene region and, the large subunit, ribonucleotide reductase; and, contains coding sequences for CSP, PfSSP2, LSA-1-repeatless, MSA-1, SERA, AMA-1 and Pfs25. That embodiment is termed NYVAC-Pf7 and is a multicomponent, multistage vaccine since it codes for and expresses sporozoite proteins, liver stage proteins, blood stage proteins and, sexual stage proteins.
摘要翻译：描述的是重组痘病毒，例如痘苗或金丝雀痘病毒，其含有来自疟原虫的外来DNA，例如编码CSP，PfSSP2，LSA-1，LSA-1-无重复，MSA-1，SERA，AMA- 1，Pfs25，MSA-1 N端p83和MSA-1 C端gp42。还描述了含有用于在接种疫苗的宿主动物中诱导免疫应答的重组痘病毒的疫苗。优选的重组体具有减毒毒力。在某些实施方案中，痘苗已经缺失或破坏了胸苷激酶基因，出血区域，A型包涵体区域，宿主范围基因区域和大亚基核糖核苷酸还原酶; 并且包含用于CSP，PfSSP2，LSA-1-无重复，MSA-1，SERA，AMA-1和Pfs25的编码序列。该实施方案称为NYVAC-Pf7，并且是多组分多级疫苗，因为其编码并表达子孢子蛋白，肝阶段蛋白质，血液阶段蛋白质和性阶段蛋白质。

7. 发明授权

US5494807A NYVAC vaccinia virus recombinants comprising heterologous inserts 失效
标题翻译： NYVAC痘苗病毒重组体包含异源插入片段
公开(公告)号：US5494807A
公开(公告)日：1996-02-27
申请号：US105483
申请日：1993-08-12
申请人： Enzo Paoletti , Marion E. Perkus , Jill Taylor , James Tartaglia , Elizabeth K. Norton , Michel Riviere , Charles de Taisne , Keith J. Limbach , Gerard P. Johnson , Steven E. Pincus , William I. Cox , Jean-Christophe F. Audonnet , Russell R. Gettig
发明人： Enzo Paoletti , Marion E. Perkus , Jill Taylor , James Tartaglia , Elizabeth K. Norton , Michel Riviere , Charles de Taisne , Keith J. Limbach , Gerard P. Johnson , Steven E. Pincus , William I. Cox , Jean-Christophe F. Audonnet , Russell R. Gettig
IPC分类号： A61K39/12 , A61K39/00 , A61K39/08 , A61K39/15 , A61K39/165 , A61K39/17 , A61K39/175 , A61K39/205 , A61K39/21 , A61K39/23 , A61K39/245 , A61K39/275 , A61K39/285 , A61K39/29 , A61P31/04 , A61P31/12 , A61P31/14 , A61P31/16 , A61P31/18 , A61P31/20 , A61P31/22 , C07H21/04 , C07K1/00 , C07K14/015 , C07K14/02 , C07K14/03 , C07K14/035 , C07K14/045 , C07K14/05 , C07K14/06 , C07K14/065 , C07K14/07 , C07K14/11 , C07K14/12 , C07K14/125 , C07K14/145 , C07K14/15 , C07K14/155 , C07K14/16 , C07K14/175 , C07K14/18 , C07K14/33 , C12N7/00 , C12N7/01 , C12N7/04 , C12N7/08 , C12N15/00 , C12N15/09 , C12N15/86 , C12N15/863 , C12P21/06 , C12R1/93 , A61K39/295 , C12N15/63
CPC分类号： C12N15/86 , C07K14/005 , C07K14/33 , A61K2039/5254 , A61K39/00 , C07K2319/00 , C07K2319/02 , C07K2319/40 , C12N2710/16122 , C12N2710/16222 , C12N2710/16622 , C12N2710/16722 , C12N2710/24022 , C12N2710/24043 , C12N2710/24122 , C12N2710/24143 , C12N2730/10122 , C12N2740/13022 , C12N2740/15022 , C12N2740/16122 , C12N2740/16222 , C12N2750/14322 , C12N2760/12122 , C12N2760/16122 , C12N2760/18122 , C12N2760/18422 , C12N2760/18722 , C12N2760/20122 , C12N2770/24122 , C12N2770/24322 , Y10S530/826
摘要： What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.
摘要翻译：描述的是具有增强的安全性的修饰载体，例如重组痘病毒，特别是重组痘苗病毒。修饰的重组病毒具有在其中灭活的非必需病毒编码的遗传功能，使得病毒具有减毒毒力。在一个实施方案中，通过删除编码毒力因子的开放阅读框来使遗传功能失活。在另一个实施方案中，通过插入失活编码毒力因子的开放阅读框来使遗传功能失活。还描述了含有在其中灭活的非必需病毒编码的遗传功能的修饰的重组病毒的疫苗，使得疫苗与已知重组病毒疫苗相比具有提高的安全性水平。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式